Phaseline

Targets › L2

L2 (Ligand-gated cation channel ZACN): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Ligand-gated cation channel that allows the movement of sodium and potassium monoatomic cations across cell membranes when activated by zinc (Zn2+), copper (Cu2+), and changes in pH. Could also transport cesium. (UniProt, Q401N2)

Open in Phaseline: the race on L2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Alabama at BirminghamTA-CIN
Recombinant fusion protein vaccine comprised of HPV16 L2, E7, and E6 proteins
E6, E7, L2Phase 1ASC-USDec 2027
University of Alabama at BirminghampNGVL4aCRTE6E7L2
DNA plasmid vaccine encoding HPV16 E6, E7, and L2 antigens
E6, E7, L2Phase 1ASC-USDec 2027

Conditions

ASC-US (2)

Modalities

protein or peptide (2)

Companies

University of Alabama at Birmingham (2)

Related targets

E6 (2) E7 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.